Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET

Diagnosis of Sceletal Metastases in c. Mammae: 18F-NaF-PET/Lowdose-CT Versus 99mTc HDP Bone Scintigraphy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01224873

Enrollment

110

Registered

2010-10-20

Start date

2010-10-31

Completion date

2013-09-30

Last updated

2011-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer, bone metastasis, comparison of diagnostic methods, bone scintigraphy, fluoride PET/CT, FDG-PET/CT

Brief summary

Breast cancer can metastasize to the bones, which leads to another treatment if bone metastases are detected. The purpose of the study is to determine, if fluoride PET/CT is superior to bone scintigraphy with technetium. On the other side, the investigators would like to see if FDG-PET/CT is a reliable alternative to dedicated bone imaging to detect bone metastases in patients with breast cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically proven c. mammae * clinically suspicion of bone metastases

Exclusion criteria

* age under 18 years * diabetes mellitus * pregnancy * other known malignant disease

Countries

Denmark

Contacts

Primary ContactChristine Winkler, Dr.

christine.winkler@rh.regionh.dk

Outcome results